PE Firms Line Up for Pharmaceutical Targets

Although pharmaceutical M&A has declined sharply over the past year, there has been an uptick in financial buyer activity in the sector in the first eight months of 2017. We don’t typically see a lot of financial buyers in this space, since they are easily outbid by strategic buyers that have the advantage of easy […]

Second Quarter Health Care M&A Spending Tanks

It’s still early yet, but we can say with confidence that the second quarter of 2015 doesn’t hold a candle to last year’s second quarter, at least dollar-wise. Last year, deal volume and value hit all-time highs for all previous Q2s, coming in at 325 deals and $135.8 billion in spending on those deals. This […]

Five Biggest Healthcare Deals in May 2015

The last week of May slowed to a crawl as far as announced health care transactions, but preliminary totals for deal volume and value indicate that May 2015 wasn’t too shabby. As of May 29, we counted 101 healthcare transactions, with a combined total of $32.4 billion. A year ago, there were 109 M&A announcements, […]

Endo Tries to Upstage Valeant’s Bid for Salix

It’s not over until the fat check arrives. That’s the story of Salix Pharmaceuticals (NASDAQ: SLXP), which last month accepted Valeant Pharmaceuticals’ (NYSE: VRX) $10.1 billion acquisition offer. Valeant thought it had snatched victory from Shire plc (NASDAQ: SHPG) and Endo International plc (NASDAQ: ENDP), which were also readying bids for the troubled Salix. Endo […]